Warfarin anticoagulation in children: is there a role for a personalized approach to dosing?

被引：4

作者：

Biss, Tina T. ^{[1
]}

Kamali, Farhad ^{[1
]}

机构：

[1] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England

来源：

PHARMACOGENOMICS | 2012年 / 13卷 / 11期

关键词：

anticoagulant; CYP2C9; pediatrics; pharmacogenetics; vitamin K; VKORC1; warfarin; VITAMIN-K ANTAGONISTS; PATIENT CHARACTERISTICS; PEDIATRIC-PATIENTS; DOSE REQUIREMENT; VKORC1; VARIABILITY; CYP2C9; IMPACT; PERFORMANCE; GENOTYPE;

D O I：

10.2217/PGS.12.92

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Studies of children receiving warfarin have shown that body size is the major predictor of warfarin dose. However, polymorphisms in the key genes ... involved in the metabolism and action of warfarin are also responsible for a significant proportion of the interindividual variability in warfarin-dose requirement.

引用

页码：1211 / 1214

页数：4

共 19 条

[11] Antithrombotic therapy in neonates and children [J].

Monagle, Paul ;

Chalmers, Elizabeth ;

Chan, Anthony ;

deVeber, Gabrielle ;

Kirkham, Fenella ;

Massicotte, Patricia ;

Michelson, Alan D. .

CHEST, 2008, 133 (06) :887S-968S

[12] Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement [J].

Moreau, Caroline ;

Bajolle, Fanny ;

Siguret, Virginie ;

Lasne, Dominique ;

Golmard, Jean-Louis ;

Elie, Caroline ;

Beaune, Philippe ;

Cheurfi, Radhia ;

Bonnet, Damien ;

Loriot, Marie-Anne .

BLOOD, 2012, 119 (03) :861-867

[13]

Nieto JA, 2012, THROMB RES

[14] In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes [J].

Nowak-Goettl, Ulrike ;

Dietrich, Kevin ;

Schaffranek, Daria ;

Eldin, Noha Sharaf ;

Yasui, Yutaka ;

Geisen, Christof ;

Mitchell, Lesley G. .

BLOOD, 2010, 116 (26) :6101-6105

[15] Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose [J].

Rieder, MJ ;

Reiner, AP ;

Gage, BF ;

Nickerson, DA ;

Eby, CS ;

McLeod, HL ;

Blough, DK ;

Thummel, KE ;

Veenstra, DL ;

Rettie, AE .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (22) :2285-2293

[16] Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation [J].

Sconce, E ;

Khan, T ;

Mason, J ;

Noble, F ;

Wynne, H ;

Kamali, F .

THROMBOSIS AND HAEMOSTASIS, 2005, 93 (05) :872-875

[17] The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:: proposal for a new dosing regimen [J].

Sconce, EA ;

Khan, TI ;

Wynne, HA ;

Avery, P ;

Monkhouse, L ;

King, BP ;

Wood, P ;

Kesteven, P ;

Daly, AK ;

Kamali, F .

BLOOD, 2005, 106 (07) :2329-2333

[18] Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin [J].

Sconce, Elizabeth ;

Avery, Peter ;

Wynne, Hilary ;

Kamali, Farhad .

BLOOD, 2007, 109 (06) :2419-2423

[19] Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients [J].

Streif, W ;

Andrew, M ;

Marzinotto, V ;

Massicotte, P ;

Chan, AKC ;

Julian, JA ;

Mitchell, L .

BLOOD, 1999, 94 (09) :3007-3014

← 1 2 →